As of 2026-03-27, the EV/EBITDA ratio of Revolution Medicines Inc (RVMD) is -28.68. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVMD's latest enterprise value is 18,356.13 mil USD. RVMD's TTM EBITDA according to its financial statements is -639.94 mil USD. Dividing these 2 quantities gives us the above RVMD EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-03-25 | -29.02 |
| 2026-03-24 | -29.40 |
| 2026-03-23 | -29.74 |
| 2026-03-20 | -29.48 |
| 2026-03-19 | -30.57 |
| 2026-03-18 | -30.20 |
| 2026-03-17 | -30.52 |
| 2026-03-16 | -30.48 |
| 2026-03-13 | -29.19 |
| 2026-03-12 | -29.26 |
| 2026-03-11 | -30.66 |
| 2026-03-10 | -30.43 |
| 2026-03-09 | -30.72 |
| 2026-03-06 | -30.29 |
| 2026-03-05 | -30.68 |
| 2026-03-04 | -31.16 |
| 2026-03-03 | -30.94 |
| 2026-03-02 | -31.29 |
| 2026-02-27 | -31.41 |
| 2026-02-26 | -31.45 |
| 2026-02-25 | -31.79 |
| 2026-02-24 | -32.28 |
| 2026-02-23 | -31.93 |
| 2026-02-20 | -31.35 |
| 2026-02-19 | -31.64 |
| 2026-02-18 | -30.72 |
| 2026-02-17 | -30.98 |
| 2026-02-13 | -29.64 |
| 2026-02-12 | -29.96 |
| 2026-02-11 | -30.16 |
| 2026-02-10 | -29.54 |
| 2026-02-09 | -29.78 |
| 2026-02-06 | -30.01 |
| 2026-02-05 | -29.59 |
| 2026-02-04 | -29.71 |
| 2026-02-03 | -29.54 |
| 2026-02-02 | -29.91 |
| 2026-01-30 | -29.84 |
| 2026-01-29 | -30.23 |
| 2026-01-28 | -29.96 |
| 2026-01-27 | -30.73 |
| 2026-01-26 | -30.10 |
| 2026-01-23 | -36.25 |
| 2026-01-22 | -36.61 |
| 2026-01-21 | -36.22 |
| 2026-01-20 | -35.81 |
| 2026-01-16 | -37.07 |
| 2026-01-15 | -37.99 |
| 2026-01-14 | -37.36 |
| 2026-01-13 | -36.96 |